当前位置: X-MOL 学术JAMA › 论文详情
New Malaria Option
JAMA ( IF 51.273 ) Pub Date : 2020-01-14 , DOI: 10.1001/jama.2019.20669
Bridget Kuehn

A newer antimalaria medication with a simplified dosing regimen may be useful in US patients as prophylaxis or as an antirelapse treatment, according to a review in the Morbidity and Mortality Weekly Report. The US Food and Drug Administration approved tafenoquine in 2018 as prophylaxis for individuals traveling to malaria-endemic areas and for antirelapse therapy for people infected with the Plasmodium vivax malaria parasite. Previously, only primaquine was available for antirelapse therapy. Most antimalarial drugs target the blood stage of the parasite. As such, malaria treatments must be given for months after infection to kill some species such as P vivax and Plasmodium ovale that can lie dormant in the liver for months and then emerge, causing a relapse, the authors explained. In 2016, these 2 species caused about 19% of the roughly 1800 imported malaria cases with an identified species of parasite in the United States. Antirelapse therapy is required for P vivax and P ovale infections and for travelers with intense or prolonged exposure to them.
更新日期:2020-01-21

 

全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
加州大学洛杉矶分校
上海纽约大学William Glover
南开大学化学院周其林
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug